ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Daiichi Sankyo Co., Ltd.

Business Summary

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2021 JPYUSD
Revenue962,516M9,075.42M
Gross Profit624,227M5,885.74M
Operating income80,179M755.99M
Income before tax73,956M697.32M
Net income75,957M716.18M
EBITDA137,561M1,297.04M
Diluted EPS39.110.36
Dividends Per Share26.990.25
Total Assets2,085.17B18,870.38M
Total liabilities807,030M7,303.43M
Total equity1,272.05B11,511.79M
Operating cash flow192,207M1,812.29M
Currency in JPYCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 955,124M 960,195M 929,717M 981,793M 962,516M
Gross Profit 605,751M 614,174M 565,112M 638,587M 624,227M
Operating income 127,875M 112,326M 90,461M 118,028M 80,179M
Income before tax 87,788M 81,021M 85,831M 141,164M 73,956M
Net income 53,466M 60,282M 93,410M 129,074M 75,957M
EBITDA 175,248M 159,006M 136,630M 170,639M 137,561M
Diluted EPS 26.48 30.36 47.95 66.26 39.11
Dividends Per Share 23.33 23.33 23.33 23.33 26.99
Total Assets 1,914.97B 1,897.75B 2,088.05B 2,105.61B 2,085.17B
Total liabilities 743,545M 764,709M 838,343M 791,549M 807,030M
Total equity 1,175.89B 1,132.98B 1,249.64B 1,305.80B 1,272.05B
Operating cash flow 136,234M 108,439M 92,033M 196,601M 192,207M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 8,820.26M 8,663.48M 8,383.78M 9,029.99M 9,075.42M
Gross Profit 5,593.91M 5,541.46M 5,095.93M 5,873.37M 5,885.74M
Operating income 1,180.88M 1,013.47M 815.73M 1,085.55M 755.99M
Income before tax 810.69M 731.02M 773.98M 1,298.34M 697.32M
Net income 493.74M 543.90M 842.33M 1,187.15M 716.18M
EBITDA 1,618.35M 1,434.65M 1,232.07M 1,569.44M 1,297.04M
Diluted EPS 0.24 0.27 0.43 0.60 0.36
Dividends Per Share 0.21 0.21 0.21 0.21 0.25
Total Assets 17,185.48M 17,844.41M 18,864.80M 19,504.59M 18,870.38M
Total liabilities 6,672.75M 7,190.49M 7,574.13M 7,332.21M 7,303.43M
Total equity 10,552.78M 10,653.33M 11,290.07M 12,095.86M 11,511.79M
Operating cash flow 1,258.07M 978.40M 829.91M 1,808.22M 1,812.29M

Valuation Measures

Mar 2021
PER82.33
ROA3.62%
ROE5.89%
Operating margin8.33%
Profit margin7.89%

Key executives

  • President, CEO & Representative Director: Sunao Manabe
  • CFO, Director, Executive Officer & Head-Management: Hiroyuki Okuzawa
  • Global Director-Research & Development: Ken Takeshita
  • Representative Director & Senior Executive Officer: Satoru Kimura
  • Director & Senior Executive Officer: Shoji Hirashima

Shareholders

  • Capital Research & Management Co. (World Investors) (6.2%)
  • Nippon Life Insurance Co. (5.5%)
  • Nomura Asset Management Co., Ltd. (5.1%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.5%)
  • Capital Research & Management Co. (Global Investors) (2.6%)
  • The Vanguard Group, Inc. (2.3%)
  • Mizuho Bank Pension Fund (2.2%)
  • Nikko Asset Management Co., Ltd. (2.1%)
  • Daiwa Asset Management Co. Ltd. (2.0%)
  • Wellington Management Co. LLP (1.8%)

Contact Details

  • Website:http://www.daiichisankyo.co.jp
  • Address: Daiichi Sankyo Head Office Bldg, A&B, 3-5-1 Nihonbashi-honcho, Tokyo, 103-8426, Japan
  • Phone: +81.3.6225.1111

Related Companies

  • Daiichi Sankyo Co. Ltd. /11 Long Listed Drugs/
  • Daiichi Sankyo Chemical Pharma Co., Ltd.
  • Daiichi Sankyo RD Novare Co., Ltd.
  • Daiichi Sankyo Biotech Co. Ltd.
  • Astellas Pharma, Inc. /3 Drug Products/
  • Daiichi Sankyo Belgium SA
  • Daiichi Sankyo Restricted Stock Compensation Plan
  • Daiichi Sankyo Pharma, Inc.
  • Novare Co. Ltd.
  • Daiichi Sankyo Pharmaceutical (Shanghai) Co. Ltd.
  • Daiichi Sankyo Venezuela SA
  • Daiichi Sankyo (Schweiz) AG
  • Daiichi Sankyo Hong Kong Ltd.
  • Daiichi Forging Dalian Co. Ltd.
  • Daiichi Sankyo Pharmaceutical (Beijing) Co. Ltd.
  • Kitasato Daiichi Sankyo Vaccine Co., Ltd.
  • Daiichi Sankyo Pension Fund
  • Daiichi Sankyo Espha Co., Ltd.
  • Daiichi Sankyo (Thailand) Ltd.
  • Daiichi Sankyo Employee Stock Ownership Plan
  • Daiichi Sankyo (China) Holdings Co., Ltd.
  • Daiichi Sankyo Ireland Ltd.
  • Sankyo Pharma Nederland BV
  • Daiichi Sankyo Taiwan Ltd.
  • NV Sankyo Pharma Belgium SA
  • Daiichi Sankyo Portugal Lda.
  • Daiichi Sankyo Austria GmbH
  • Daiichi Sankyo Nederland BV
  • Daiichi Sankyo Logistics Co. Ltd.
  • Daiichi Sankyo Italia SpA

Competitors

  • AstraZeneca PLC
  • Boryung Pharmaceutical Co., Ltd.
  • Hanmi Pharmaceutical Co., Ltd.
  • LegoChem Biosciences, Inc.
  • Reata Pharmaceuticals, Inc. Class A
  • MacroGenics, Inc.
  • Sutro Biopharma, Inc.
  • CrystalGenomics Inc.
  • Agios Pharmaceuticals, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • CHO Pharma, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Bolt Biotherapeutics, Inc.
  • Allogene Therapeutics, Inc.
  • Aprea Therapeutics, Inc.
  • BioCardia, Inc.
  • Forma Therapeutics Holdings, Inc.
  • ImmunoGen, Inc.
  • Qurient Co., Ltd.
  • Nuvation Bio Inc Class A
  • Heidelberg Pharma AG
  • Amphastar Pharmaceuticals Inc
  • Collegium Pharmaceutical, Inc.
  • Esperion Therapeutics, Inc.
  • Molecular Templates, Inc.
  • PTC Therapeutics, Inc.
  • Springworks Therapeutics, Inc.
  • Vincerx, Inc
  • Aptose Biosciences Inc.
  • Blueprint Medicines Corp.
Last Updated on 28 Sep, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more